ArticleNeuroscience2017
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Article in Neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Glioblastoma research on zebrafish xenograft models: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Pooled it
- Pooled it
- 3D-Printed Scaffold-Based Glioblastoma Spheroid In Vitro Model for Drug Screening Application.Annals of biomedical engineering · 2026Article
- Unique gene patterns lead to distinct functional phenotypes and chemosensitivity profiles among subclones obtained from a single glioblastoma cell line.Acta biochimica et biophysica Sinica · 2025Article
- Macrophages directly kill bladder cancer cells through TNF signaling as an early response to BCG therapy.Disease models & mechanisms · 2024Article
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Article
- PotentFrontiers in oncology · 2023Article
- Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients.Biomedicines · 2022Article
- Orthotopic Transplantation of Human Paediatric High-Grade Glioma in Zebrafish Larvae.Brain sciences · 2022Article
- Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.Neuro-oncology · 2022Article
- Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish.Disease models & mechanisms · 2022Article
- TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion.Molecules (Basel, Switzerland) · 2021Article
- Cellular and Molecular Mechanisms Underlying Glioblastoma and Zebrafish Models for the Discovery of New Treatments.Cancers · 2021Review
- Cancer stem cells: a major culprit of intra-tumor heterogeneity.American journal of cancer research · 2021Review
- Antiangiogenic molecules from marine actinomycetes and the importance of using zebrafish model in cancer research.Heliyon · 2020Review
- Single-cell imaging of human cancer xenografts using adult immunodeficient zebrafish.Nature protocols · 2020Article
- Zebrafish Xenografts for Drug Discovery and Personalized Medicine.Trends in cancer · 2020Review
- Considering the Experimental use of Temozolomide in Glioblastoma Research.Biomedicines · 2020Review
- Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GBM) is a highly aggressive brain cancer with limited treatments and poor patient survival. GBM tumors are heterogeneous containing a complex mixture of dividing cells, differentiated cells, and cancer stem cells. It is unclear, however, how these different cell populations contribute to tumor growth or whether they exhibit differential responses to chemotherapy. Here we set out to address these questions using a zebrafish xenograft transplant model (Welker et al., 2016). We found that a small population of differentiated vimentin-positive tumor cells, but a majority of Sox2-positive putative cancer stem cells, were dividing during tumor growth. We also observed co-expression of Sox2 and GFAP, another suggested marker of glioma cancer stem cells, indicating that the putative cancer stem cells in GBM9 tumors expressed both of these markers. To determine how these different tumor cell populations responded to chemotherapy, we treated animals with temozolomide (TMZ) and assessed these cell populations immediately after treatment and 5 and 10days after treatment cessation. As expected we found a significant decrease in dividing cells after treatment. We also found a significant decrease in vimentin-positive cells, but not in Sox2 or GFAP-positive cells. However, the Sox2-positive cells significantly increased 5days after TMZ treatment. These data support that putative glioma cancer stem cells are more resistant to TMZ treatment and may contribute to tumor regrowth after chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.